<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, March 31, 2020 (HealthDay News) — Real-world data support the benefit of using the Medtronic MiniMed 670G insulin pump system for glycemic control in type 1 diabetes, according to a study presented at the virtual meeting of The Endocrine Society, held from March 28 to 31.<\/p>\n
Robert Alan Vigersky, M.D., and colleagues from Medtronic Diabetes in Washington, D.C., analyzed system data for 118,737 individuals with type 1 diabetes aged \u22657 years who enabled Auto Mode on their MiniMed 670G system. The authors sought to determine the mean percentage of overall time spent <54 mg\/dL\/<70 mg\/dL (time below range [TBR]), between 70 and 180 mg\/dL (TIR), and >180 mg\/dL\/>250 mg\/dL (time above range [TAR]). The impact of Auto Mode was examined among 51,254 individuals with at least seven days of sensor glucose data for Auto Mode turned ON and turned OFF.<\/p>\n
The researchers found that the system data TIR was 71.3 percent. User-wise data of Auto Mode OFF versus ON showed a mean of 70.3 percent of time spent in Auto Mode; the analysis showed an increase in TIR from 60.9 to 69.9 percent and decreases in both TBR and TAR for Auto Mode versus Manual Mode.<\/p>\n
“Our results demonstrate that the glycemic control using the MiniMed 670G in the real world is excellent,” Vigersky said in a statement.<\/p>\n
The study was funded by Medtronic Diabetes.<\/p>\n
Press Release<\/a><\/p>\n